Skip to main content

Dabigatran Disease Interactions

There are 4 disease interactions with dabigatran.

Major

Dabigatran (applies to dabigatran) valvular heart disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Prosthetic Heart Valves, Mitral Stenosis

The use of dabigatran is contraindicated in patients with mechanical prosthetic valves. The use of dabigatran for the prophylaxis of thromboembolic events in patients with atrial fibrillation in the setting of other forms of valvular heart disease, including the presence of a bioprosthetic heart valve has not been studied and it is not recommended.

References

  1. "Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim (2010):
Major

Thrombin inhibitors (applies to dabigatran) active bleeding

Major Potential Hazard, High plausibility. Applicable conditions: Coagulation Defect

The use of thrombin inhibitors is contraindicated in the presence of active major bleeding. Additionally, these drugs should be used with caution in patients with disease states associated with an increased risk of bleeding.

References

  1. "Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim (2010):
  2. "Product Information. Bivalirudin (bivalirudin)." Fresenius Kabi USA, LLC (2016):
Moderate

Dabigatran (applies to dabigatran) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The anticoagulant activity and half-life of dabigatran may increase in patients with renal impairment. It is recommended to decrease the dose in patients with severe renal impairment (CrCl 15-30 mL/min). No dose adjustment is recommended in patients with mild or moderate renal impairment. Dosing recommendations for patients with CrCl <15 mL/min or on dialysis has not been established. Care should be exercised when using this agent in patients with renal impairment or on dialysis.

References

  1. "Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim (2010):
Moderate

Oral anticoagulants (applies to dabigatran) antiphospholipid syndrome

Moderate Potential Hazard, Moderate plausibility.

Direct acting oral anticoagulants including factor Xa inhibitors and some thrombin inhibitors as dabigatran, are not recommended for use in patients with antiphospholipid syndrome (APS). Treatment with these drugs has been associated with increased rates of recurrent thrombotic events, especially in patients with triple positive APS.

References

  1. "Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim (2010):
  2. "Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals SUPPL-39 (2022):
  3. "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb SUPPL-34 (2021):
  4. "Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc. SUPPL-17 (2021):
View all 4 references

Dabigatran drug interactions

There are 284 drug interactions with dabigatran.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer